Back to Search
LORI WIRTH, MD
MD
Medical Oncology Physician
NPI: 1750344008IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
205729(MA)
Education
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
Class of 1997
Research & Publications (20)
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
PMID 19138978·Cancer Prev Res (Phila)·2008
3-trial
Recent advances in combined modality therapy for locally advanced head and neck cancer.
PMID 18045072·Curr Cancer Drug Targets·2007
6-review
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
PMID 16172459·J Clin Oncol·2005
3-trial
Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
PMID 15084386·Lung Cancer·2004
8-other
Progress and perspectives in chemoprevention of head and neck cancer.
PMID 12820777·Expert Rev Anticancer Ther·2003
6-review
Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.
PMID 12738723·Clin Cancer Res·2003
3-trial
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
PMID 19564535·J Clin Oncol·2009
3-trial
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
PMID 19634161·Cancer·2009
3-trial
Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
PMID 19211798·Proc Natl Acad Sci U S A·2009
8-other
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
PMID 19179556·Ann Oncol·2009
3-trial
Induction chemotherapy in locally advanced head and neck cancer: a new standard of care?
PMID 19010265·Hematol Oncol Clin North Am·2008
6-review
Motesanib diphosphate in progressive differentiated thyroid cancer.
PMID 18596272·N Engl J Med·2008
3-trial
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.
PMID 18468812·Int J Radiat Oncol Biol Phys·2008
3-trial
A phase II study of gefitinib in patients with advanced thyroid cancer.
PMID 17985985·Thyroid·2008
3-trial
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
PMID 16785415·Arch Otolaryngol Head Neck Surg·2006
8-other
Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer.
PMID 16730530·Otolaryngol Head Neck Surg·2006
8-other
Delayed diagnosis of pediatric bipolar disorder in a community mental health setting.
PMID 16728912·J Psychiatr Pract·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST SW 430, DFCI HEAD AND NECK ONCOLOGY
BOSTON, MA 02115 - Phone
- (617) 632-3090
Quick Facts
- NPI
- 1750344008
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 20
Are you this provider?
Claim Your Profile